Regulation and implications of inflammatory lymphangiogenesis

Trends in Immunology

Volumn 33, Issue 7, 2012, Pages 350-356

  Kim, Honsoul ^a,b   Kataru, Raghu P ^a   Koh, Gou Young ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 3;

ADAPTIVE IMMUNITY; ADULTHOOD; ANTIGEN PRESENTATION; CELL MIGRATION; CHRONIC INFLAMMATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; LYMPH NODE; LYMPHANGIOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SKIN INFLAMMATION; VACCINATION;

ADAPTIVE IMMUNITY; ANIMALS; CELL MOVEMENT; HUMANS; INFLAMMATION; LYMPHANGIOGENESIS; LYMPHATIC VESSELS;

EID: 84862648524     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.03.006     Document Type: Review

References (82)

1. Alitalo K. The lymphatic vasculature in disease. Nat. Med. 2011, 17:1371-1380.
2. Vigl B., et al. Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell migration in a stimulus-dependent manner. Blood 2011, 118:205-215.
3. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
4. Mouta C., Heroult M. Inflammatory triggers of lymphangiogenesis. Lymphat. Res. Biol. 2003, 1:201-218.
5. Robbins S.L., et al. Robbins and Cotran Pathologic Basis of Disease 2010, Saunders/Elsevier.
6. Avraham T., et al. Fibrosis is a key inhibitor of lymphatic regeneration. Plast. Reconstr. Surg. 2009, 124:438-450.
7. Paupert J., et al. Lymphangiogenesis in post-natal tissue remodeling: lymphatic endothelial cell connection with its environment. Mol. Aspects Med. 2011, 32:146-158.
8. Wick N., et al. Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro. Physiol. Genomics 2007, 28:179-192.
9. Alitalo K., et al. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
10. Karkkainen M.J., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004, 5:74-80.
11. Haiko P., et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell Biol. 2008, 28:4843-4850.
12. Kajiya K., et al. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005, 24:2885-2895.
13. Cueni L.N., Detmar M. The lymphatic system in health and disease. Lymphat. Res. Biol. 2008, 6:109-122.
14. He Y., et al. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 2004, 64:3737-3740.
15. Kerjaschki D., et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat. Med. 2006, 12:230-234.
16. Maruyama K., et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 2005, 115:2363-2372.
17. Lee J.Y., et al. Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization. Circulation 2010, 122:1413-1425.
18. Pflicke H., Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med. 2009, 206:2925-2935.
19. Baluk P., et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 2007, 204:2349-2362.
20. Dejana E., et al. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev. Cell 2009, 16:209-221.
21. Norrmen C., et al. Biological basis of therapeutic lymphangiogenesis. Circulation 2011, 123:1335-1351.
22. Huggenberger R., et al. An important role of lymphatic vessel activation in limiting acute inflammation. Blood 2011, 117:4667-4678.
23. Baluk P., et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J. Clin. Invest. 2005, 115:247-257.
24. Guo R., et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 2009, 60:2666-2676.
25. Huggenberger R., et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J. Exp. Med. 2010, 207:2255-2269.
26. Flister M.J., et al. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood 2010, 115:418-429.
27. Kunstfeld R., et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004, 104:1048-1057.
28. Wirzenius M., et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 2007, 204:1431-1440.
29. Mounzer R.H., et al. Lymphotoxin-alpha contributes to lymphangiogenesis. Blood 2010, 116:2173-2182.
30. Pytowski B., et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J. Natl. Cancer Inst. 2005, 97:14-21.
31. Kataru R.P., et al. T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity 2011, 34:96-107.
32. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat. Rev. Immunol. 2009, 9:618-629.
33. Alvarez D., et al. Mechanisms and consequences of dendritic cell migration. Immunity 2008, 29:325-342.
34. Junt T., et al. Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat. Rev. Immunol. 2008, 8:764-775.
35. Ji R.C. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol. Histopathol. 2009, 24:377-384.
36. Angeli V., et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006, 24:203-215.
37. Shrestha B., et al. B cell-derived vascular endothelial growth factor A promotes lymphangiogenesis and high endothelial venule expansion in lymph nodes. J. Immunol. 2010, 184:4819-4826.
38. Kataru R.P., et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood 2009, 113:5650-5659.
39. Kim K.E., et al. Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm. Am. J. Pathol. 2009, 175:1733-1745.
40. Chyou S., et al. Fibroblast-type reticular stromal cells regulate the lymph node vasculature. J. Immunol. 2008, 181:3887-3896.
41. Halin C., et al. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood 2007, 110:3158-3167.
42. Mumprecht V., et al. Inflammation-induced lymph node lymphangiogenesis is reversible. Am. J. Pathol. 2011, 180:874-879.
43. Zhu M., et al. LIGHT regulates inflamed draining lymph node hypertrophy. J. Immunol. 2011, 186:7156-7163.
44. Zhu M., Fu Y.X. The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling. Immunol. Rev. 2011, 244:75-84.
45. Jawdat D.M., et al. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J. Immunol. 2006, 177:1755-1762.
46. McLachlan J.B., et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat. Immunol. 2003, 4:1199-1205.
47. Zampell J.C., et al. Lymphatic function is regulated by a coordinated expression of lymphangiogenic and anti-lymphangiogenic cytokines. Am. J. Physiol. Cell Physiol. 2012, 302:C392-C404.
48. Oka M., et al. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 2008, 111:4571-4579.
49. Clavin N.W., et al. TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2113-H2127.
50. Avraham T., et al. Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair. Am. J. Pathol. 2010, 177:3202-3214.
51. Ou J., et al. Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin alpha9. J. Cell Biochem. 2011, 112:2106-2114.
52. Yao L.C., et al. Steroid-resistant lymphatic remodeling in chronically inflamed mouse airways. Am. J. Pathol. 2010, 176:1525-1541.
53. Ji R.C. Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol. Life Sci. 2012, 69:897-914.
54. Angeli V., Randolph G.J. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res. Biol. 2006, 4:217-228.
55. Kang S., et al. Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages. Blood 2009, 113:2605-2613.
56. Randolph G.J., et al. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 2005, 5:617-628.
57. Forster R., et al. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 2008, 8:362-371.
58. Johnson L.A., et al. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J. Exp. Med. 2006, 203:2763-2777.
59. Lammermann T., et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 2008, 453:51-55.
60. Miteva D.O., et al. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ. Res. 2010, 106:920-931.
61. Tal O., et al. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J. Exp. Med. 2011, 208:2141-2153.
62. Nykanen A.I., et al. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 2010, 121:1413-1422.
63. Chen L., et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 2004, 10:813-815.
64. Muniz L.R., et al. A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J. Immunol. 2011, 187:828-834.
65. Ziegler E., et al. CCR7 signaling inhibits T cell proliferation. J. Immunol. 2007, 179:6485-6493.
66. Burrell B.E., et al. Tolerance and lymphoid organ structure and function. Front. Immunol. 2011, 2:1-16.
67. Cohen J.N., et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J. Exp. Med. 2010, 207:681-688.
68. Baluk P., et al. TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J. Clin. Invest. 2009, 119:2954-2964.
69. von der Weid P.Y., et al. Role of the lymphatic system in the pathogenesis of Crohn's disease. Curr. Opin. Gastroenterol. 2011, 27:335-341.
70. Alexander J.S., et al. Emerging roles of lymphatics in inflammatory bowel disease. Ann. N.Y. Acad. Sci. 2010, 1207(Suppl. 1):E75-E85.
71. Halin C., et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am. J. Pathol. 2008, 173:265-277.
72. Ebata R., et al. Increased production of vascular endothelial growth factor-d and lymphangiogenesis in acute Kawasaki disease. Circ. J. 2011, 75:1455-1462.
73. Hirono K., Ichida F. Possible new role of vascular endothelial growth factor-D during the acute phase of Kawasaki disease. Circ. J. 2011, 75:1324-1325.
74. Wang H.W., et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet. 2004, 36:687-693.
75. Yin N., et al. Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation 2011, 92:25-30.
76. Dietrich T., et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J. Immunol. 2010, 184:535-539.
77. Kerjaschki D., et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J. Am. Soc. Nephrol. 2004, 15:603-612.
78. Schonthaler H.B., et al. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21264-21269.
79. Kajiya K., et al. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J. Invest. Dermatol. 2009, 129:1292-1298.
80. Albuquerque R.J., et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 2009, 15:1023-1030.
81. Yan Z.X., et al. Angiopoietin-2 promotes inflammatory lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H215-H223.
82. Reddy S.T., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25:1159-1164.